title: Intravitreal triamcinolone for cancer-associated retinopathy refractory to systemic therapy.
abstract: OBJECTIVE
  The purpose of this study is to report the use of intravitreal triamcinolone for treatment of cancer-associated retinopathy (CAR) refractory to systemic therapy.
  
  
  METHODS
  This was a retrospective chart review study.
  
  
  RESULTS
  A 67-year-old man presented with cancer-associated retinopathy with antibodies against a 46-kDa retinal protein, alpha enolase. There was disease progression despite therapy with mycophenolate and intravenous immunoglobulin. Serial intravitreal injections of triamcinolone resulted in restoration of photoreceptor anatomy on optical coherence tomography and visual improvement. The patient's vision was preserved at 20/40 OD and 20/32 OS until his death from lung cancer 31 months after CAR diagnosis.
  
  
  CONCLUSIONS
  Intravitreal triamcinolone may be beneficial for maintenance of vision in patients with CAR.
authors.affiliation: Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, 243 Charles Street, Boston, MA, 02114, USA.
authors.forename: Nancy
authors.initials: N
authors.lastname: Huynh
authors.forename: Yevgeniy
authors.initials: Y
authors.lastname: Shildkrot
authors.forename: Ann-Marie
authors.initials: AM
authors.lastname: Lobo
authors.forename: Lucia
authors.initials: L
authors.lastname: Sobrin